Variant Summary
- HGVS
- —
- Variant Type(s)
- missense_variant
- Evidence Items
- 11
Evidence Level Distribution
Level A: 1Level B: 9Level D: 1
Evidence Items
Showing CIViC evidence rows where gene = KRAS and variant = Exon 2 Mutation.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab | 5 |
| B | Predictive | Supports | Resistance | Pancreatic Cancer | Gemcitabine,Erlotinib | 4 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 3 |
| B | Prognostic | Does Not Support | Poor Outcome | Colorectal Cancer | 3 | |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab | 3 |
| D | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Vemurafenib | 3 |
| B | Predictive | Does Not Support | Resistance | Pancreatic Carcinoma | Erlotinib | 3 |
| B | Prognostic | Supports | Poor Outcome | Pancreatic Carcinoma | 3 | |
| B | Prognostic | Does Not Support | Poor Outcome | Rectum Cancer | 2 | |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Irinotecan,Selumetinib | 1 |
| B | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Regorafenib Anhydrous | 1 |